

COMPOSITIONS AND METHODS FOR MODULATING NEURAL SPROUTING

This application claims priority under 35 U.S.C.
5 §119(e)(1) to provisional application number 60/083,472,
filed 4/29/98.

Field of the Invention

10 The present invention is directed towards methods and
compositions for inhibiting neural sprouting in neurons that
have been subjected to botulinum toxin. Also disclosed are
methods and compositions for extending the period of time
during which treatment of nerve cells with botulinum toxin
15 is effective to prevent innervation of a cell or tissue,
such as muscle cells or tissue. Such methods and
compositions are effective in the treatment of spasms or
muscular tetanus. Disclosed as well are methods and
compositions for stimulating neural outgrowth.

20

Background of the invention

Neurotoxins, such as those obtained from *Clostridium*
botulinum and *Clostridium tetanus*, are highly potent and
specific poisons of neural cells. These Gram positive
25 bacteria secrete two related but distinct toxins, each
comprising two disulfide-linked amino acid chains: a light
chain (L) of about 50 KDa and a heavy chain (H) of about 100
KDa, which are wholly responsible for the symptoms of these
diseases.

30 The tetanus and botulinum toxins are among the most
lethal substances known to man, having a lethal dose in
humans of between 0.1 ng and 1 ng per kilogram of body

weight. Tonello et al., *Adv. Exp. Med. & Biol.* 389:251-260 (1996). Both toxins function by inhibiting neurotransmitter release in affected neurons. The tetanus neurotoxin (TeNT) acts mainly in the central nervous system, while botulinum neurotoxin (BoNT) acts at the neuromuscular junction by inhibiting acetylcholine release from the axon of the affected neuron into the synapse, resulting in a localized flaccid paralysis. The effect of intoxication on the affected neuron is long-lasting and has been thought to be irreversible.

The tetanus neurotoxin (TeNT) is known to exist in one immunologically distinct type; the botulinum neurotoxins (BoNT) are known to occur in seven different immunogenic types, termed BoNT/A through BoNT/G. While all of these types are produced by isolates of *C. botulinum*, two other species, *C. baratii* and *C. butyricum* also produce toxins similar to /F and /E, respectively. See e.g., Coffield et al., *The Site and Mechanism of Action of Botulinum Neurotoxin in Therapy with Botulinum Toxin* 3-13 (Jankovic J. & Hallett M. eds. 1994), the disclosure of which is incorporated herein by reference.

Regardless of type, the molecular mechanism of intoxication appears to be similar. In the first step of the process, the toxin binds to the presynaptic membrane of the target neuron through a specific interaction between the heavy chain and a cell surface receptor; the receptor is thought to be different for each type of botulinum toxin and for TeNT. The carboxy terminus of the heavy chain appears to be important for targeting of the toxin to the cell surface.

In the second step, the toxin crosses the plasma membrane of the poisoned cell. The toxin is first engulfed by the cell through receptor-mediated endocytosis, and an endosome containing the toxin is formed. The toxin then
5 escapes the endosome into the cytoplasm of the cell. This last step is thought to be mediated by the amino terminus of the heavy chain, which triggers a conformational change of the toxin in response to a pH of about 5.5 or lower. Endosomes are known to possess a proton pump which decreases
10 intra-endosomal pH. The conformational shift exposes hydrophobic residues in the toxin, which permits the toxin to embed itself in the endosomal membrane. The toxin then translocates through the endosomal membrane into the cytosol.

15 The last step of the mechanism of botulinum toxin activity appears to involve reduction of the disulfide bond joining the heavy and light chain. The entire toxic activity of botulinum and tetanus toxins is contained in the light chain of the holotoxin; the light chain is a zinc
20 (Zn++) endopeptidase which selectively cleaves proteins essential for recognition and docking of neurotransmitter-containing vesicles with the cytoplasmic surface of the plasma membrane, and fusion of the vesicles with the plasma membrane. TxNT, BoNT/B BoNT/D, BoNT/F, and BoNT/G cause
25 degradation of synaptobrevin 2 (also called vesicle-associated membrane protein (VAMP)), a synaptosomal membrane protein. Most of the VAMP present at the cytosolic surface of the synaptic vesicle is removed as a result of any one of these cleavage events. Each toxin specifically cleaves a
30 different bond.

BoNT/A and /E selectively cleave the plasma membrane-associated protein SNAP-25; this protein is bound to and present on the cytosolic surface of the plasma membrane. BoNT/C cleaves syntaxin, an integral protein having most of its mass exposed to the cytosol. Syntaxin interacts with the calcium channels at presynaptic terminal active zones. See Tonello et al., *Tetanus and Botulism Neurotoxins in Intracellular Protein Catabolism* 251-260 (Suzuki K & Bond J. eds. 1996), the disclosure of which is incorporated by reference as part of this specification. BoNT/C₁ also cleaves SNAP-25 at a peptide bond next to that cleaved by BoNT/A.

Both TeNT and BoNT are taken up at the neuromuscular junction. BoNT remains within peripheral neurons, and blocks release of the neurotransmitter acetylcholine from these cells. Through its receptor, TeNT enters vesicles that move in a retrograde manner along the axon to the soma, and is discharged into the intersynaptic space between motor neurons and the inhibitory neurons of the spinal cord. At this point, TeNT binds receptors of the inhibitory neurons, is again internalized, and the light chain enters the cytosol to block the release of the inhibitory neurotransmitters 4-aminobutyric acid (GABA) and glycine from these cells. Id.

Because of its specifically localized effects, dilute preparations of BoNT have been used since 1981 as therapeutic agents in the treatment of patients having various spastic conditions, including strabismus (misalignment of the eye), buphthalmos (involuntary eyelid closure) and hemifacial spasm. See e.g., Borrodi et al.,

Pharmacology and Histology Botulinum Toxin in Therapy with Botulinum Toxin 3-13 (Jankovic J. & Hallett M. eds. 1994), incorporated by reference herein. Of the seven toxin types, BoNT/A is the most potent of the BoNTs, and the most well
5 characterized. Intramuscular injection of spastic tissue with dilute preparations of BoNT/A has been also used effectively to treat spasticity due to brain injury, spinal cord injury, stroke, multiple sclerosis and cerebral palsy.

The extent of paralysis depends on both the dose and dose
10 volume delivered to the target site. Typically, the neurotoxin is administered in a preparation that also contains several non-toxic proteins as well, including hemagglutins and associated glycoproteins that assist in maximizing its stability and presentation to the target
15 motor neuron.

Typically there is a 24 to 72 hour delay between the administration of the toxin and the onset of the clinical effect. Exposure to the toxin causes denervation atrophy. See e.g., Dutton J., *Acute and Chronic Effects of Botulinum Toxin in the Management of Blepharospasm*, in *Therapy with Botulinum Toxin* at 199, incorporated by reference herein.
20 Although the therapeutic application of BoNT has been extraordinarily effective, what side effects have been observed are mainly immediate effects associated with the treatment event itself. Peripheral effects causing weakness
25 in adjacent muscles may sometimes occur; these effects usually do not persist beyond 1 to two weeks. The specific manifestations of these effects upon adjacent muscle groups depend upon the particular indication being treated. For
30 example, patients treated for blepharospasm sometimes

experience ptosis, and swallowing problems may occur after injection of neck muscles for torticollis.

Other possible consequences of treatment include the potential for overdosage through miscalculation or
5 differences in activity between different preparations of the toxin, generalized fatigue, and the potential for allergic reactions.

A feature of treatment with BoNT/A, and other clostridial neurotoxin types, is that the paralytic action
10 is temporary with symptoms reappearing in patients within a few months after toxin injection. This characteristic has been thought to be associated with the observed sprouting of nascent, synaptically active processes at the neuromuscular junction (NMJ). The production of such sprouts following
15 BoNT/A therapeutic treatment has appeared to contribute to the reinnervation of the treated tissue and therefore the need for repeated serial injections of the toxin.

The duration of paralytic action caused by clostridial neurotoxin and the extent of sprouting, appears to depend on
20 the neurotoxin subtype studied and therefore appears to be related to the specific SNARE target cleaved by each neurotoxin. Thus, BoNT/A and BoNT/C₁, which cleave the t-SNARE protein SNAP-25 within one amino acid of each other, cause a long lasting paralysis with a long average sprout
25 length observed. BoNT/F, which cleaves the v-SNARE protein VAMP, causes a paralysis of shorter duration and sprouts of shorter average length. BoNT/E, which cleaves SNAP-25 at a different position than that of BoNT/A and BoNT/C₁ (thereby liberating a SNAP fragment of different size from the plasma
30 membrane), has a short duration period of about 5 days, and

virtually no neural sprouting is observed. Without wishing to be bound by theory, these observations suggest that neural sprouting and duration of paralysis are normally related events, and that the cleavage products of BoNT
5 proteolytic digestion (i.e., the liberated fragment or the membrane-bound fragment) can directly or indirectly regulate, or be coregulated with, neural sprouting.

It would therefore be advantageous to design a method whereby the sprouting phenomenon may be uncoupled from
10 duration of therapeutic effect, and thus delayed, blocked or attenuated so as to prolong the effects of injection of tissue with toxin. Although the experiments described herein utilize a BoNT/A preparation, it will be recognized by those of skill in the art that the methods shown herein
15 will be suitable for employment using other clostridial toxins, such as BoNT/B through /G, and TeNT, in which a sprouting pathway can be observed.

Additionally, it would be advantageous to provide herein compositions effective for the inhibition or
20 prevention of the sprouting phenomenon. Such compositions and methods would lessen the need for patients to undergo repeated neurotoxin treatment.

Summary of the Invention

25

The present invention concerns methods for increasing the period of time between therapeutic treatments of neural tissue with a clostridial neurotoxin; thus the method provides a method of increasing the effectiveness of such
30 treatments. A direct advantage of such methods is an

increased therapeutic "life" and a concomitant lessening in the required frequency of treatment of the patient with neurotoxin. Reducing frequency of treatment would provide less opportunity for a patient to experience the side
5 effects described above that are observed following treatment, but which tend to subside long before the effectiveness of the toxin in the target area has subsided. Additionally, reduced frequency of treatment provides less opportunity for miscalculation of dosage amount and other
10 treatment-specific risks.

Accordingly, an aspect of the invention concerns a composition comprising a first agent comprising a clostridial neurotoxin for use as a therapeutic agent and a second agent able to extend the duration of therapeutic
15 benefit of said first agent, wherein the second agent is effective to attenuate the production of nerve terminal sprouts following treatment of a neuromuscular junction with the clostridial neurotoxin.

In a particular embodiment of this aspect of the
20 invention, the first and second agent may comprise a single entity which is provided the patient in a single treatment session. For example, the entity may comprise a single molecule, or a disulfide-linked multichain polypeptide. Additionally or alternatively, the entity may comprise one
25 or more adsorbed or linked heterogroup, such as a small organic molecule or a nucleic acid linked thereto. The entity preferably comprises both the receptor binding and translocation activities of a clostridial heavy chain and an active portion of a clostridial toxin light chain. The
30 light chain may also comprise an auxiliary enzymatic

activity, such as a ribonuclease, which specifically cleaves a nucleic acid encoding an intraneuronal factor which is responsible for the expression, activation and/or secretion of neurotrophic factors or cell adhesion molecules. In a preferred embodiment, such an auxiliary activity is provided by a ribozyme. By ribozyme is meant a nucleic acid or nucleic acid analog having a sequence-specific nuclease activity; the construction and use of ribozymes are well known in the art; see e.g., Cech, T., *Science* 236:1532-1539 (1987); Cech, T. R., *Curr. Opin. Struct. Biol.* 2:605-609 (1992); and Usman et al., *Nucleic Acids & Mol. Biol.* 10:243-264 (1996), the disclosures of which are hereby incorporated by reference herein. By nucleic acid analog is meant a polymeric molecule able to form a sequence-specific hybrid with a target single-stranded nucleic acid; such analogs may contain modified nucleotides (or ribonucleotides) such as 3'-O methyl nucleotides, phosphorothioate modified nucleotides, methylphosphonate nucleotides, or nucleotide bases separated by a peptide-like bond.

Alternatively, a nucleic acid or nucleic acid analog comprised in the single entity referred to above may be an antisense agent able to selectively bind to a nucleic acid encoding an intraneuronal factor which is responsible for the expression, activation and/or secretion of neurotrophic factors or cell adhesion molecules. This antisense agent may further provide a double-stranded substrate for the action of an intracellular RNase H activity. Details concerning certain embodiments of these aspects of the invention are contained in e.g., Dolly et al., International Publication No. WO95/32738, entitled *Modification of*

Clostridial Toxins for Use as Transport Proteins and Uherek et al., *J. Biol. Chem.* 273:8835-8841 (1998). These two references are incorporated by reference as part of the present application.

5 A nucleic acid moiety linked polypeptide portion of the entity may encode a protein or polypeptide having the ability to be expressed within a neuron and to directly or indirectly regulate the expression, activation and/or secretion of neurotrophic factors or cell adhesion
10 molecules.

 In preferred aspects of the invention, the second agent is selected from the group consisting of agents able to compete with, down-regulate, or neutralize the effects of: IGFI, IGF II, a neurotrophic factor, leukemia inhibitory
15 factor, a nerve cell adhesion molecule and neural agrin. In a more preferred aspect of the invention, the neurotrophic factor is selected from the group consisting of: ciliary neurotrophic factor, NT-3, NT-4, and brain-derived neurotrophic factor and/or the nerve cell adhesion molecule
20 is selected from the group consisting of tenascin-C, ninjurin, neural cell adhesion molecule.

 Applicants have surprisingly discovered that recovery of neural function following poisoning of nerve terminals with clostridial neurotoxin involves two distinct and
25 apparently coordinated events. First, the poisoned endplate becomes synaptically inactive. Shortly thereafter the endplate elaborates thin nascent axon neural processes. These processes or "sprouts" are synaptically competent after about 14 days following treatment with clostridial
30 neurotoxin. The sprouts continue growing, reaching a

maximal length and level of complexity after about 42 days following treatment with neurotoxin. During this time, the endplate remains synaptically inactive.

Secondly, after about 42 days, the sprouts begin to
5 regress, shortening in length and decreasing in complexity.

At the same time, the original endplate begins to become synaptically active, undergoing synaptic vesicle turnover. The increase in such turnover reaches that of the unpoisoned endplate after about 91 days post-treatment, at
10 approximately the same time that the sprouting phenomenon has completely regressed, and no sprouts can be observed. These findings are reported in DePaiva et al., *Proc. Nat'l. Acad. Sci.* 96:3200-3205 (March 1999), which is hereby incorporated by reference herein.

15 These observations are diametrically opposed to the prevailing wisdom in the art, in which it has largely been assumed that the original endplate is permanently inactivated upon treatment with clostridial toxin, and that all return of synaptic activity is due to extension of
20 sprouts to compensate for the lack of a neurologically functional endplate. However, as indicated, the old paradigm has been shown by the present Applicants to be in error, in that the poisoned endplate regains neurological function over time, while the axon sprouts regress so that
25 after a given time period the nerve terminal appears essentially as it did prior to treatment. Therefore, Applicants have discovered that, far from being a permanent feature, the axonal sprouts assume a temporary role in the rehabilitation of the poisoned endplate.

30 Although not wishing to be limited by theory,

Applicants believe that these results indicate that the two events outlined above are temporally coordinated, in that a blockage of the neural sprouting phenomenon would delay or block the recovery of the functional endplate. Such

5 temporal coordination could be due to the secretion of one or more factor by the damaged neural endplate (or the inactive muscle fiber) that has neurotrophic effects resulting in the formation of neural sprouts; these sprouts may then elaborate a factor (either the same or different

10 from the first factor) which promotes continued sprouting. This factor may be produced during neurite sprouting in amounts sufficient for the reinnervation of the neurotoxin-damaged endplate even after treatment with clostridial toxin. Thus, treatment of cells with an agent able to block

15 neural sprouting would also delay or otherwise attenuate the ability of the treated endplate to experience return of neurological function, and in fact may well block such return altogether.

As indicated, the signaling event indicating the

20 initiation of the neural sprouting phenomenon appears to be mediated by a cytokine or other intercellular messenger. One such agent, agrin, appear to be an important player, if not the key molecule, in the formation of the neuromuscular junction in development, and in neuromuscular regeneration.

25 See Ruegg M.A. and Bixby J. L., *Trends in Neurol. Sci.* 21:22-27 (1998), the disclosure of which is incorporated herein by reference. Agrin appears to be present in a number of isoforms, which result from alternative mRNA splicing. Soluble agrin isolated from synaptic basal lamina extracts

30 (to which it binds following secretion) is able to induce

the aggregation of acetylcholine receptors in the postsynaptic portions of muscle cells. Agrin present in motor neuron terminals (n-agrin) contains an insert, relative to other agrin species, in a region termed the B/z region; this insert is important in conferring the ability on n-agrin to aggregate acetylcholine receptors in postsynaptic tissue. Neural agrin is released by the motor-nerve terminal and is believed by Applicants to induce post-synaptic specialization and up-regulation of other factors, such as muscle-diffusible factors, involved in the neural sprouting response.

It is anticipated that methods which interfere with the sprouting phenomenon (such as by the preventing the action of agrin) would delay the return of innervation to cells which are controlled by neurons which have been therapeutically poisoned (i.e., by BoNT or TeNT) or otherwise damaged. This is because, as indicated above, the rate of return of neural function appears to be partly dependent upon the presence of synaptically active sprouts. Additionally, agents to be used in the inhibition of sprouting may very well also delay or prevent the recovery of neural activity of the endplate following poisoning.

Thus utilization of such methods would therefore be expected to extend the effective period of treatment of tissue with a clostridial toxin, by delaying the regeneration of active neuromuscular synapses, both through inhibition of sprouting and of recovery of the poisoned endplate.

Detailed Description of the Invention

This invention is drawn to methods and compositions for increasing the therapeutic effectiveness of treatment of tissue with clostridial neurotoxin. This increase in effectiveness is made possible by the surprising discovery that regeneration of neural tissue damaged by treatment with clostridial neurotoxin is a complex occurrence in which two coordinated events take place.

In the first of these events, the poisoned neuromuscular endplate becomes synaptically inactive, demonstrating no exocytosis of synaptic vesicles and thus no transport of intracellular acetylcholine. In four days after treatment, the endplate begins to form neural sprouts that are shown to release and regenerate synaptic vesicles.

These sprouts grow in length and complexity until approximately 42 days following treatment with the neurotoxin; at this point the neural sprouts begin to regress and shorten. At ninety-one days following treatment, the neural sprouts can no longer be seen.

In the second event, simultaneously with the beginning of regression of the neural sprouts, the synaptically inactive endplate begins to regain the ability to release acetylcholine and begin to recycle synaptic vesicles. This ability, which begins at relatively low levels, increases over the time period indicated above. At approximately 91 days following treatment with clostridial neurotoxin the endplate is histologically and synaptically indistinguishable from the condition of the endplate before treatment with clostridial neurotoxin.

These findings indicate that one may therapeutically

intervene at one of the major steps of the sprouting phenomenon to prevent or attenuate the neural sprouting as a method of extending the effective period during which tissue treated with the toxin remains paralyzed. In an initial
5 step, the muscle cells surrounding the neural endplate respond, either sensing the inactive muscle or in response to a signal from the poisoned nerve terminal, by producing muscle-derived diffusable factors. The expression of a number of muscle-derived signaling factors appears to be
10 upregulated by muscle inactivation; such factors include insulin-like growth factors (IGF-1 and IGF-2). A factor such as neural agrin is believed to be the initial signal directing the muscle cell to produce the IGF molecules. Reports have demonstrated that IGF I and IGF II effect
15 neurite outgrowth in cultured BoNT/A treated dorsal root ganglia, and also are able to stimulate the initial sprouting response in paralyzed mouse gluteus muscle. See Caroni, P. and Schneider, C. J. *Neurosci.* 14:3378-3388 (1994) and Caroni, P., et al. *J. Cell Biol.* 125:893-902
20 (1994).

Thus, blocking the effects of such muscle derived diffusable factors that positively affect neurite outgrowth and sprouting may attenuate not only clostridial neurotoxin-induced sprouting, but may also delay the eventual recovery
25 of neurotransmission at the poisoned nerve terminals. Such blocking may occur through the use of antibodies specific for the muscle derived diffusable factor in question, or that are common to such muscle derived diffusable factors. Alternatively, there are naturally occurring binding
30 proteins, such as the IGF binding proteins IGF-BP 4 and IGF-

BP 5, which can bind to, and, therefore block, the neurotrophic effect of such diffusable factors.

IGF-BP 4 has an amino acid sequence (from the amino terminus) of:

5

MLPLGLVAALLLAAGPGPSLGDEAIHCPPCSEELARCRPPVGCEELVREPGCGCCATCA
LGLGMPCGVYTPRCGSLRCYPPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDE
GDHPNNSFSPCSAHDRLQKHFAKIRDRSTSGGKMKVNGAPREDARPVPPQGSCQSELHR
ALERLAASQSRTHEDLYIIPNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGG
LEPKGELDCHQLADSFRE

10

(SEQ ID NO: 1)

This is encoded within the nucleotide base sequence (from 5' to 3') of:

15

GTGCCCTCCG CCGCTCGCCC GCGCGCCCGC GCTCCCCGCC TCGCCCCAGC
GCCCCGCGCC CGCGCCCCAG TCCTCGGGCG GTCATGCTGC CCCTCTGCCT
CGTGGCCGCG CTGCTGCTGG CCGCCGGGCC CGGGCCGAGC CTGGGCGACG
20 AAGCCATCCA CTGCCCCGCC TGCTCCGAGG AGAAGCTGGC GCGCTGCCGC
CCCCCGTGG GCTGCGAGGA GCTGGTGCGA GAGCCGGGCT GCGGCTGTTG
CGCCACTTGC GCCCTGGGCT TGGGGATGCC CTGCGGGGTG TACACCCCCC
GTTGCGGCTC GGGCCTGCGC TGCTACCCGC CCCGAGGGGT GGAGAAGCCC
CTGCACACAC TGATGCACGG GCAAGGCGTG TGCATGGAGC TGGCGGAGAT
25 CGAGGCCATC CAGGAAAGCC TGCAGCCCTC TGACAAGGAC GAGGGTGACC
ACCCCAACAA CAGCTTCAGC CCCTGTAGCG CCCATGACCG CAGGTGCCTG
CAGAAGCACT TCGCCAAAAT TCGAGACCGG AGCACCAGTG GGGGCAAGAT
GAAGGTCAAT GGGGCGCCCC GGGAGGATGC CCGGCCTGTG CCCCAGGGCT
CCTGCCAGAG CGAGCTGCAC CGGGCGCTGG AGCGGCTGGC CGCTTCACAG
30 AGCCGCACCC ACGAGGACCT CTACATCATC CCCATCCCCA ACTGCGACCG
CAACGGCAAC TTCCACCCCA AGCAGTGTCA CCCAGCTCTG GATGGGCAGC
GTGGCAAGTG CTGGTGTGTG GACCGGAAGA CGGGGTGAA GCTTCCGGGG
GGCCTGGAGC CAAAGGGGGA GCTGGACTGC CACCAGCTGG CTGACAGCTT
TCGAGAGTGA GGCCTGCCAG CAGGCCAGGG ACTCAGCGTC CCCTGCTACT
35 CCTGTGCTCT GGAGGCTGCA GAGCTGACCC AGAGTGGAGT CTGAGTCTGA
GTCCTGTCTC TGCCTGCGGC CCAGAAGTTT CCCTCAAATG CGCGTGTGCA
CGTGTGCGTG TGCCTGCGTG TGTGTGTGTT TGTGAGCATG GGTGTGCCCT
TGGGGTAAGC CAGAGCCTGG GGTGTTCTCT TTGGTGTAC ACAGCCCAAG
AGGACTGAGA CTGGCACTTA GCCCAAGAGG TCTGAGCCCT GGTGTGTTTC
40 CAGATCGATC CTGGATTCAC TCACTCACTC ATTCCTTCAC TCATCCAGCC
ACCTAAAAC ATTTACTGAC CATGTACTAC GTGCCAGCTC TAGTTTTACG
CCTTGGGAGG TTTTATTCTG ACTTCCTCTG ATTTTGGCAT GTGGAGACAC
TCCTATAAGG AGAGTTCAAG CCTGTGGGAG TAGAAAATC TCATTCCCAG

AGTCAGAGGA GAAGAGACAT GTACCTTGAC CATCGTCCTT CCTCTCAAGC
 TAGCCAGAGG GTGGGAGCCT AAGGAAGCGT GGGGTAGCAG ATGGAGTAAT
 GGTCACGAGG TCCAGACCCA CTCCCAAAGC TCAGACTTGC CAGGCTCCCT
 TTCTCTTCTT CCCAGGTCC TTCCTTTAGG TCTGGTTGTT GCACCATCTG
 5 CTTGGTTGGC TGGCAGCTGA GAGCCCTGCT GTGGGAGAGC GAAGGGGGTC
 AAAGGAAGAC TTGAAGCACA GAGGGCTAGG GAGGTGGGGT ACATTTCTCT
 GAGCAGTCAG GGTGGGAAGA AAGAATGCAA GAGTGGACTG AATGTGCCTA
 ATGGAGAAGA CCCACGTGCT AGGGGATGAG GGGCTTCCTG GGTCTGTTC
 CCTACCCCAT TTGTGGTCAC AGCCATGAAG TCACCGGGAT GAACCTATCC
 10 TTCCAGTGGC TCGCTCCCTG TAGCTCTGCC TCCCTCTCCA TATCTCCTTC
 CCCTACACCT CCCTCCCCAC ACCTCCCTAC TCCCCTGGGC ATCTTCTGGC
 TTGACTGGAT GGAAGGAGAC TTAGGAACCT ACCAGTTGGC CATGATGTCT TTTCT

(SEQ ID NO: 3)

15

IGFBP 5 has an amino acid sequence (from the amino terminus) of:

MVLLTAVLLLLLAAYAGPAQSLGSFVHCEPCDEKALSMCPPSPLGCELVKEPGCGCCMTCA
 20 LAEGQSCGVYTERCAQGLRCLPRQDEEKPLHALLHGRGVCLNEKSYREQVKIERDSREHE
 EPTTSEMAEETYSPIKIFRPKHTRISELKAEAVKKDRRKLTQSKFVGAENTAHPRIISA
 PEMRQESEQGPCRRHMEASLQELKASPRMVPRAVYLPNCDRKGFYKRKQCKPSRGRKRG
 CWCVDKYGMKLPMEYVDGDFQCHTFDSSNVE

25 (SEQ ID No. 2)

and is encoded within a nucleotide base sequence (from 5' to 3') of:

30 GGGGAAAAGA GCTAGGAAAG AGCTGCAAAG CAGTGTGGGC TTTTTCCTT
 TTTTGTCTCT TTTCAATTAC CCCTCCTCCG TTTTCACCCT TCTCCGGACT
 TCGCGTAGAA CCTGCGAATT TCGAAGAGGA GGTGGCAAAG TGGGAGAAAA
 GAGGTGTTAG GGTGTTGGGT TTTTTTGT TTTTGTGTT TTTTAAATTT
 CTTGATTCA ACATTTTCTC CCACCCTCTC GGCTGCAGCC AACGCCTCTT
 35 ACCTGTTCTG CGGCGCCGCG CACCGCTGGC AGCTGAGGGT TAGAAAGCGG
 GGTGTATTTT AGATTTTAAG CAAAATTTT AAAGATAAAT CCATTTTCT
 CTCCCACCCC CAACGCCATC TCCACTGCAT CCGATCTCAT TATTTCTGGT
 GTTGCTTGGG GGTGAACAAT TTTGTGGCTT TTTTCCCCT ATAATTCTGA
 CCCGCTCAGG CTTGAGGGTT TCTCCGGCCT CCGCTCACTG CGTGCACCTG
 40 GCGCTGCCCT GCTTCCCCCA ACCTGTTGCA AGGCTTTAAT TCTTGCAACT
 GGGACCTGCT CGCAGGCACC CCAGCCCTCC ACCTCTCTCT ACATTTTTCG
 AAGTGTCTGG GGGAGGGCAC CTGCTCTACC TGCCAGAAAT TTAAACAA
 AAACAAAAAC AAAAAAATCT CCGGGGGCCC TCTTGGCCCC TTTATCCCTG
 CACTCTCGCT CTCCTGCCCC ACCCCGAGGT AAAGGGGGCG ACTAAGAGAA

GATGGTGTG CTCACCGCGG TCCTCCTGCT GCTGGCCGCC TATGCGGGGC
CGGCCCAGAG CCTGGGCTCC TTCGTGCACT GCGAGCCCTG CGACGAGAAA
GCCCTCTCCA TGTGCCCCC CAGCCCCCTG GGCTGCGAGC TGGTCAAGGA
GCCGGGCTGC GGCTGCTGCA TGACCTGCGC CCTGGCCGAG GGGCAGTCGT
5 GCGGCGTCTA CACCGAGCGC TGCGCCCAGG GGCTGCGCTG CCTCCCCCGG
CAGGACGAGG AGAAGCCGCT GCACGCCCTG CTGCACGGCC GCGGGGTTTG
CCTCAACGAA AAGAGCTACC GCGAGCAAGT CAAGATCGAG AGAGACTCCC
GTGAGCACGA GGAGCCCACC ACCTCTGAGA TGGCCGAGGA GACCTACTCC
CCCAAGATCT TCCGGCCCAA ACACACCCGC ATCTCCGAGC TGAAGGCTGA
10 AGCAGTGAAG AAGGACCGCA GAAAGAAGCT GACCCAGTCC AAGTTTGTGC
GGGGAGCCGA GAACACTGCC CACCCCCGGA TCATCTCTGC ACCTGAGATG
AGACAGGAGT CTGAGCAGGG CCCCTGCCGC AGACACATGG AGGCTTCCCT
GCAGGAGCTC AAAGCCAGCC CACGCATGGT GCCCCGTGCT GTGTACCTGC
CCAATTGTGA CCGCAAAGGA TTCTACAAGA GAAAGCAGTG CAAACCTTCC
15 CGTGGCCGCA AGCGTGGCAT CTGCTGGTGC GTGGACAAGT ACGGGATGAA
GCTGCCAGGC ATGGAGTACG TTGACGGGGA CTTTCAGTGC CACACCTTCG
ACAGCAGCAA CGTTGAGTGA TGCCTCCCCC CCCAACCTTT CCCTCACCCC
CTCCCACCCC CAGCCCCGAC TCCAGCCAGC GCCTCCCTCC ACCCCAGGAC
GCCACTCATT TCATCTCATT TAAGGGAAAA ATATATATCT ATCTATTTGA
20 GGAAAAAAA AAAAAAAA AA

(SEQ ID NO: 4)

These binding proteins can be made synthetically or
25 cloned and produced for therapeutic purposes, while a cell
line producing a desired monoclonal antibody can be
maintained for relatively large-scale antibody production.
Cloning and general antibody methodologies are commonplace
in the art; such methodologies are disclosed within Sambrook
30 et al., *Molecular Cloning: A Laboratory Manual* (2nd ed. Cold
Spring Harbor Laboratory Press 1989), the disclosure of
which is hereby incorporated by reference as part of this
disclosure.

Rather than using competitive methods, another aspect
35 of the invention involves the use of a cholinergic special
transporter to insert a gene which produces inactive
receptors for one or more factor involved in promotion of
neural sprouting. Such receptors would maintain high

specific binding constants to their ligands, but the biological activity of the receptors would be abrogated; such receptors could be easily be generated and screened through the introduction of mutations in the nucleotide
5 sequence encoding the protein, and assaying the mutants for binding strength and biological activity. Alternatively, the neurotrophic activities of factors produced by the neural endplate or nascent sprouts may be inhibited through intracellular targeting and delivery of a competitive
10 inhibitor, ribozyme, transcriptional suppresser or other agent specifically able to block or attenuate such activities, as described above. Such intracellular targeting is disclosed in references such as, e.g., Dolly et al., International Patent Publication No. WO95/32738,
15 previously incorporated by reference herein.

The second point at which intervention in the sprouting phenomenon may be made is during the stage of axonal outgrowth and arbor development. At this stage such outgrowth has already been initiated, but auxiliary factors
20 appear to be necessary in order to maintain axonal growth. A number of factors are known to affect the rates of outgrowth, and may also effect the survivability of many types of neurons. Such factors include ciliary neurotrophic factor (CNTF); neurotrophins, including NT-3, NT-4, and
25 brain-derived neurotrophic factor (BDNF); and leukemia inhibitory factor (LIF). Not only are these factors important in establishing an initial rate of axonal outgrowth, but they appear to either directly or indirectly stimulate their own production -- therefore blocking the
30 initial outgrowth of sprouts may be essential in preventing

further propagation through the continued expression of such factors.

The same methods as disclosed above can be used to prevent one or more of the agents listed above to manifest its activity. As would be expected by those of skill in the art in light of the present disclosure, such agents, destroy or bind to, and therefore attenuate the activity of these factors or their block their ability to bind to their receptors, or inactive forms of their receptors, would be useful when used in conjunction with a clostridial neurotoxin to prevent or reduce the rate of sprouting of neurites from the poisoned or damaged endplate.

The third stage at which the sprouting phenomenon may be attenuated or inhibited concerns the binding of axons to the extracellular matrix. Axons are guided to cellular processes containing the appropriate neurotransmitter receptors by binding to components of the extracellular matrix. Such binding involves a variety of cell-borne or matrix associated adhesion molecules. Tenascin-C is an extracellular matrix component derived from Schwann cells that appears to bind neural processes. Ninjurin is a cell surface adhesion molecule that is up-regulated following peripheral nerve injury and thought to be involved in axonal guidance. See Araki, T., et al., *J. Biol. Chem.* 272:21373-21380 (1997), incorporated by reference herein. Similarly, neural-cell adhesion molecule (N-CAM), is an adhesion molecule which is thought to be involved in binding of neural sprouts to the extracellular matrix. The same techniques indicated above may be employed to prevent the expression or inhibit the activity of these molecules when

used as part of a clostridial neurotoxin therapy.

Thus, in one aspect the present invention is drawn to a method for extending the effective period during which tissue treated with clostridial toxin is paralyzed, comprising: Contacting said tissue with a composition comprising an agent able to prevent the neuroregenerative activity of a polypeptide selected from the group consisting of IGF-1, IGF-2, ciliary neurotrophic factor, NT-3, NT-4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin.

In one preferred embodiment, the agent comprises a polypeptide able to bind to IGF-1 and/or IGF-2 in a manner that prevents an IGF molecule from binding to or activating a cell surface receptor involved in the initiation of neural sprouting. In a most preferred embodiment the polypeptide comprises at least a portion of a amino acid sequence selected from the group consisting of: IGFBP-4 (SEQ ID NO: 1) or IGFBP5 (SEQ ID NO: 2). Preferably said portion comprises at least 10 contiguous amino acids of said sequence; more preferably said portion comprises at least 20 contiguous nucleotides of said sequence. Most preferably, the portion comprises an amino acid sequence selected from the group consisting of the entire amino acid sequence of IGFBP-4 or IGFBP-5.

Treatment of cells with such a composition may be accomplished either before or simultaneously with treatment with clostridial toxin. Preferably, the clostridial toxin is a botulinum toxin. Even more preferably, the botulinum toxin comprises BoNT/A. In other embodiments, the

clostridial toxin is TeNT. Agent which are able to bind to any of these factors in a manner that inhibits their neurotrophic activity, or which bind to the receptors for such factors, would, in light of the present application, be
5 expected to function as agents for extending the effective period between treatments of tissue with a neurotoxin.

Another embodiment comprises a cholinergic specific transporter joined to a gene encoding a gene which produces an inactive receptor for one or more factor involved in
10 promotion of neural sprouting when delivered to a neural cell in vivo. Preferably the receptors maintain high specific binding constants to said factor(s) and the biological activity of the receptor is reduced or absent. In a particularly preferred embodiment the transporter
15 comprises some or all of a clostridial neurotoxin heavy chain, although other transporters such as the diphtheria toxin transporter may be effective in this regard as well.

In another embodiment the invention comprises a cholenergic specific transporter that is covalently or non-
20 covalently joined to a nucleic acid which comprises a ribozyme or antisense nucleic acid able to specifically destroy the nucleic acids encoding neurotrophic agents or their receptors. Said joining may be made through methods including, but not limited to, covalent bonding or
25 electrostatic forces.

In another embodiment, the present invention is drawn to the methods for stimulating the outgrowth of neural sprouts from damaged neural tissue. Such methods could be effective ways of increasing the rate at which reinnervation
30 occurs after a neural injury. These methods comprise:

Contacting said tissue with a composition comprising a polypeptide which comprises a neurotrophically active domain derived from an agent selected from a group consisting of IGF-1, IGF-2, ciliary neurotrophic factor, NT-3, NT-4, brain
5 derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin. Such damage may be a result of neurotoxin poisoning or due to a traumatic event, including but not limited to nerve or spinal cord crush injuries, traumatic
10 brain injuries, glaucoma-induced damage to the retina and/or optic nerve, or surgical trauma or injury.

The following examples illustrate various embodiments of the present invention, and are not intended to limit the scope of the invention, which is solely defined by the
15 claims which conclude this specification.

Example 1

Blepharospasm is a medical condition characterized by
20 uncontrolled eyelid movement. In its early stages, the condition is characterized by excessive blinking or fluttering of the eyelids. The condition is generally a progressive one, in which excessive blinking is replaced in the later stages with spasms of eye closure that interfere
25 with visual function. The spasms become more frequent and severe, and involve the preseptal, pretarsal, and orbicularis oculi muscle. The condition often results in functional blindness relatively quickly (in a matter of two to three years) after the symptoms are first encountered.

A patient suffering from moderate idiopathic blepharospasm is treated with injections of BoNT/A toxin preparation containing non-toxic proteins and hemagglutins in sterile saline. Alternatively, the same toxin
5 preparation without hemagglutins may be used. The injections are generally in the volume of 100 μ l; and each injection contains 1.25 to 2.5 units of the toxin preparation. The injections are made into the pretarsal orbicularis oculi of the upper lid laterally and medially
10 and in the lower lid laterally and medially. Additionally, 2.5 unit injections (100 μ l each) are made lateral to the lateral canthus and into the brow medially. Total amount of BoNT/A toxin injected is roughly 6.25 to 12.5 units per eye. The Bo/A toxin is provided in a sterile, preservative-
15 free saline, and the same solution is used to dilute the BoNT/A toxin if the master preparation of it is too concentrated.

Following injection the treated muscles are sufficiently paralyzed due to this treatment to alleviate
20 the major symptoms of blepharospasm. Some mild concomitant weakness in the surrounding muscle tissue is observed; these side effects are mild and tolerated well by the patient. The effect of this treatment lasts approximately 8 weeks, and must be repeated at the end of this time to maintain the
25 beneficial effects.

Example 2

A patient with blepharospasm is pre-treated with BoNT/A toxin as indicated in Example 1 with the following
5 difference. Prior to injection with BoNT/A toxin preparation, the patient is given a ten-fold excess of IGFBP-4, having an amino acid sequence of SEQ ID NO: 1. The binding protein preparation is dissolved in sterile, preservative-free saline. Each injection is in the same
10 area as the toxin injections that follow the pre-treatment; the volume of each injection is 100 µl. The BoNT/A toxin preparation is injected ten minutes after the injection of the IGFBT 4 injection.

The patient's therapeutic response to the BoNT/A toxin
15 is similar to that seen in Example 1. The duration of the benefit provided by the BoNT/A toxin treatment is extended to 12 weeks or more, during which time no further injection need be made.

20

Example 3

A patient with blepharospasm is pre-treated with BoNT/A toxin as indicated in Example 1 with the following
25 difference. The BoNT/A toxin has been modified to have joined thereto a nucleic acid comprising a ribozyme specifically targeted to enzymatically destroy neural agrin mRNA. No supplemental injections are made.

The patient's therapeutic response to the BoNT/A toxin
30 is similar to that seen in Example 1. The duration of the benefit provided by the BoNT/A toxin treatment is extended

to 12 weeks or more, during which time no further injection need be made.

Example 4

5

A patient with blepharospasm is pre-treated with BoNT/A toxin as indicated in Example 1 with the following difference. The BoNT/A toxin has been modified to have joined thereto a nucleic acid encoding an inactive
10 neurotrophin receptor which retains the ability to bind its target neurotrophin. No supplemental injections are made.

The patient's therapeutic response to the BoNT/A toxin is similar to that seen in Example 1. The duration of the benefit provided by the BoNT/A toxin treatment is extended
15 beyond that seen with BoNT/A alone, during which time no further injection need be made.

It will be understood that, while reference is made to BoNT/A in the Examples above, any other of the species of botulinum toxins (e.g., BoNT/B through G) could be
20 substituted therefor, with appropriate adjustments possibly necessary due to differences in specific activity of the toxin. Additionally, the light chain segment could be derived from any clostridial neurotoxin (or other neurotoxin) , with the heavy chain retaining the motor
25 neuron receptor binding and exo-vesicular transport activities retained from the BoNT heavy chain.

These Examples are not intended to exhaust the embodiments of the present invention, and the invention is not to be seen as limited thereby. Further embodiments will

be disclosed within the claims that conclude this
specification.